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Abstract: Although the current literature associates polycystic ovarian syndrome (PCOS) with 
chronic inflammation, the evidence for this link remains inconclusive and its causal nature remains 
unclear. The purpose of this systematic review was to assess the inflammatory status in PCOS 
women and to determine whether it is related to PCOS or to its associated adiposity. We searched 
electronic databases including PUBMED, EMBASE and MEDLINE, SCOPUS, DynaMed plus, TRIP, 
ScienceDirect and Cochrane Library, for studies investigating C-reactive protein (CRP) and other 
inflammatory makers in PCOS women versus healthy controls. Quality and risk of bias for selected 
studies were assessed using the modified Newcastle–Ottawa scale. CRP data were extracted and 
pooled using RevMan for calculation of the standardized mean difference (SMD) and 95% confi-
dence interval (CI). Eighty-five eligible studies were included in the systematic review, of which 63 
were included in the meta-analysis. Pooled analysis of the 63 studies revealed significantly higher 
circulating CRP in PCOS women (n = 4086) versus controls (n = 3120) (SMD 1.26, 95%CI, 0.99, 1.53). 
Sensitivity meta-analysis of 35 high quality studies including non-obese women showed signifi-
cantly higher circulating CRP in PCOS women versus controls (SMD 1.80, 95%CI, 1.36, 2.25). In 
conclusion, circulating CRP is moderately elevated in PCOS women independent of obesity, which 
is indicative of low-grade chronic inflammation. 
Keywords: polycystic ovarian syndrome; chronic inflammation; inflammatory markers; C-reactive 
protein; insulin resistance; obesity 
 
1. Introduction 
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder affecting 
women with a prevalence of 15–20% amongst reproductive age women according to the 
Rotterdam diagnostic criteria [1–3], 83% of women with anovulatory infertility [4] and 
89% of hyperandrogenic women [5]. The syndrome is characterized by a varied combina-
tion of clinical (anovulation and hyperandrogenism), biochemical (excess serum luteiniz-
ing hormone and androgen concentrations) and ovarian morphological (polycystic ova-
ries) features [6]. Hyperandrogenism has been reported in about 80% of PCOS women [1] 
with hirsutism being the most common androgenic feature affecting 70% of cases [7]. Alt-
hough insulin resistance is not one of the Rotterdam diagnostic criteria, it has been re-
ported in up to 70% of women with PCOS [8–10]. The syndrome is well-known to nega-
tively affect the psychological and emotional wellbeing of women due to its distressing 
reproductive and androgenic symptoms [11]. 
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PCOS has been associated with significant long-term metabolic and cardiovascular 
morbidities, possibly due to insulin resistance [6]. It has also been associated with chronic 
low-grade inflammation, which is thought to contribute to the long-term cardiovascular 
risks [12,13]. 
Despite its high prevalence, the underlying mechanisms of PCOS remain uncertain. 
A significant body of evidence implicates androgen excess and insulin resistance in its 
pathogenesis. Several studies have reported a positive correlation between chronic low-
grade inflammation and hyperandrogenism in PCOS women. However, the causal nature 
of this association remains uncertain [12]. 
Our group and others have recently shown increased androgen synthesis in subcu-
taneous adipose tissue (SAT) that could contribute to PCOS related hyperandrogenaemia 
[14,15]. Adipose tissue is also recognised as an important site for excess production of pro-
inflammatory mediators with subsequent chronic inflammation in women with PCOS as 
well as other insulin resistant conditions such as obesity [16]. Activation of inflammatory 
pathways in adipocytes has been found to impair triglyceride storage with increased re-
lease of free fatty acids, which could induce insulin resistance [17]. The nature of the as-
sociation between hyperandrogenaemia, insulin resistance and chronic inflammation re-
mains to fully understood. 
Low grade chronic inflammation is often assessed primarily by measuring serum 
levels of C-reactive protein (CRP) in addition to several other inflammatory markers. CRP 
is a liver-derived acute phase protein produced in response to release of interleukin-6 (IL-
6) from activated immune cells such as macrophages and from adipocytes [18,19]. In-
creased serum CRP level has been strongly linked to long-term health risks in women 
with obesity and type 2 diabetes and cardiovascular disease (CVD) [20–22]. 
The status of circulating CRP and other inflammatory markers in PCOS women has 
previously been investigated in many studies with conflicting results. While some studies 
reported elevated CRP levels in PCOS women [23,24], others showed no differences in 
circulating CRP between women with and without PCOS [25,26]. A systematic review and 
meta-analysis involving 31 studies was published on this topic in 2011 providing evidence 
for increased circulating CRP (96% higher than controls) and other inflammatory markers 
in PCOS [27]. However, since that review there have been over 100 published studies as-
sessing CRP in PCOS women utilising more advanced CRP assays. The purpose of the 
current meta-analysis was therefore to assess the inflammatory status as determined by 
circulating CRP in women with PCOS based on the most recent studies. 
2. Results 
2.1. Search Results 
Our search yielded 1444 articles, which came down to 673 after exclusion of dupli-
cates. Screening of these 673 articles revealed 193 irrelevant articles, which were excluded. 
The full texts of the remaining 481 papers were carefully reviewed for eligibility criteria. 
Of these, 385 articles did not meet the inclusion criteria and were excluded. Three further 
articles [28–30] were excluded as each of them involved participants who were included 
in another larger article by the same research group [31–33]. The authors of these studies 
were contacted to ascertain if their cohorts of participants were different in each study, 
but no reply was received. Eight other articles neither matched their PCOS women and 
healthy controls for BMI nor adjusted their analysis for BMI differences [34–41]. In total, 
396 articles were excluded and 85 met the inclusion criteria and were included in this 
review (Figure 1). 




Figure 1. PRISMA Flow chart. 
2.1.1. Risk of Bias and Quality Assessment of Selected Studies 
Table 1 shows the results of quality scores of all 85 studies in this review. 
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Table 1. Modified Newcastle–Ottawa Scale for risk of bias and quality assessment of the included 
studies. 








Cascella, 2008 [31] ** ** ** 6 
Makedos, 2011 [32] ** ** *** 7 
Aydogdu, 2012 [33] *** ** ** 7 
Tarkun, 2004 [42] ** ** ** 6 
Diamanti-Kandarakis, 2006 [43] *** ** *** 8 
Topcu, 2006 [44] ** ** ** 6 
Moran, 2007 [45] *** * ** 6 
Ruan, 2007 [46] ** ** ** 6 
Costa, 2008 [47] ** ** ** 6 
Heutling, 2008 [48] *** * ** 6 
Gen, 2008 [49] ** ** ** 6 
Jakubowska, 2008 [50] ** ** ** 6 
Zwirksa-Korczala, 2008 [51] *** ** ** 7 
Çapoğlu, 2009 [52] *** * ** 6 
Kaya, 2009 [53] *** ** ** 7 
Chen, 2009 [54] *** ** *** 8 
Samy, 2009 [55] *** ** *** 8 
Soares, 2009 [56] *** ** *** 8 
Verit, 2009 [57] ** ** ** 6 
Gowri, 2010 [58] ** ** ** 6 
Nikołajuk, 2010 [59] ** ** ** 6 
Tan, 2010 [60] ** ** ** 6 
TürkçüoĞlu, 2010 [61] *** * *** 6 
Caglar, 2011 [62] *** * ** 6 
Fulghesu, 2011 [63] ** ** ** 6 
Hu, 2011 [64] *** ** *** 8 
Li, 2011 [65] *** * ** 6 
Lindholm, 2011 [66] ** * ** 5 
Mannerås-Holm, 2011 [67] *** * ** 6 
Ngo, 2011 [68] ** * ** 5 
Torun, 2011 [69] *** ** *** 8 
Xiong, 2011 [70] *** * ** 6 
Yang, 2011 [71] *** * ** 6 
Deveer, 2012 [72] ** ** ** 6 
Elkholi, 2012 [73] ** ** * 5 
Güdücü, 2012 [74] *** ** *** 8 
Iuhas, 2012 [75] *** ** * 6 
Kim, 2012 [76] ** * * 4 
Rashad, 2012 [77] **** ** ** 8 
Tao, 2012 [78] **** ** ** 8 
Dehdashtihaghighat, 2013 [79] *** ** ** 7 
Xia, 2013 [80] *** - * 4 
Kahal, 2013 [81] ** ** ** 6 
Rey-Roldan, 2013 [82] ** ** ** 6 
Tan, 2013 [83] *** * ** 6 
Yildir, 2013 [84] ** * *** 6 
Covington, 2014 [85] ** * *** 6 
Guducu, 2014 [86] **** ** *** 9 
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Kurt, 2014 [87] *** ** *** 8 
Porwal, 2014 [88] *** ** ** 7 
Sahin, 2014 [89] *** ** ** 7 
Stabile, 2014 [90] ** * ** 4 
Sumithra, 2014 [91] *** * ** 6 
Barcellos, 2015 [92] ** ** ** 6 
Daskalopoulos, 2015 [93] ** * * 4 
Demir, 2015 [94] *** * ** 6 
Güdücü, 2015 [95] *** ** *** 8 
Santos, 2015 [96] *** ** ** 7 
Sharma, 2015 [97] *** - * 4 
Yilmaz, 2015 [98] *** ** *** 8 
Calan, 2016 [99] *** ** ** 7 
Durmus, 2016 [100] **** ** *** 9 
Isıka, 2016 [101] *** * ** 6 
Kumar, 2016 [102] *** ** *** 8 
Kume, 2016 [103] *** ** ** 7 
Mishra, 2016 [104] **** ** *** 9 
Ozturk, 2016 [105] *** ** ** 8 
Temur, 2016 [106] *** ** *** 8 
Victor, 2016 [107] *** ** *** 8 
Deng, 2017 [108] *** ** *** 8 
Duan, 2017 [109] *** ** ** 7 
Abiad, 2018 [110] ** ** ** 6 
Kalyan, 2018 [111] *** ** *** 8 
Shorakae, 2018 [112] *** * ** 6 
Arpacı, 2019 [113] *** ** ** 7 
Demir, 2019 [114] *** ** *** 8 
Eken, 2019 [115] *** ** ** 7 
Ganie, 2019 [116] *** * * 5 
Kim, 2019 [117] *** ** ** 7 
Maidana, 2019 [118] *** * ** 6 
Sánchez-Ferrer, 2019 [119] *** * ** 6 
Alissa, 2020 [120] *** * *** 7 
Godtfredsen, 2020 [121] *** * ** 6 
González, 2020 [122] ** * *** 6 
Sadeghi, 2020 [123] *** ** *** 8 
Asterisks (*) indicate the star rating for each study with a maximum of four stars for se-
lection, two for comparability, and three for outcome criteria.  
2.1.2. Excluded Studies 
Of the 396 excluded articles, 138 were not comparative studies, 62 were abstracts with 
incomplete data, 27 were reviews, 19 were animal studies, and 150 had other exclusion 
criteria as detailed in Figure 1. 
2.1.3. Included Studies 
Characteristics of the 85 included studies are shown in Table 1. Of these, 45 studies 
provided data on other inflammatory markers such as IL-6, TNF-α, adiponectin, etc., as 
summarised in Table 2. 
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Table 2. Characteristics and CRP results of 85 studies included in the systematic review and meta-analysis. 














Age & BMI 
Matching or 
Adjusting 
Cascella, 2008 [31] Turkey Case–control 200 100 Not specified Nil 1.9 ± 0.8 0.8 ± 0.4 <0.001 ↑ mg/L Both matched 
Makedos, 2011 [32] Greece Case–control 188 43 INA Nil 0.55 ± 0.08 0.27 ± 0.08 <0.001 ↑ mg/L Both matched 
Aydogdu, 2012 [33] Turkey Case–control 40 40 Hs-EIA Nil 1.9 ± 1.6 1.0 ± 1.0 0.002 ↑ mg/L Both matched 
Tarkun, 2004 [42] Turkey Case–control 37 25 CLIA Nil <0.25> <0.09> <0.007 ↑ mg/dl Both matched 
Diamanti-Kanda-
rakis, 2006 [43] 
Greece Interventional 62 45 Hs-ELISA Nil 1.31 ± 0.22 0.92 ± 0.27 0.005 ↑ mg/dl Both matched 
Topcu, 2006 [44] Turkey Case–control 28 26 ITA Nil 2.5 ± 1.8 1.7 ± 1.2 >0.05 NSD mg/dl Both matched 
Moran, 2007 [45] Australia Case–control 17 15 ITA BMI > 35 5.5 ± 3.1 4.9 ± 3.0 0.603 NSD mg/dl 
BMI matched 
Age, not matched 
Ruan, 2007 [46] China Case–control 74 51 ITA Nil ((2.13)) ((0.86)) <0.001 ↑ mg/L Both matched 
             
Costa, 2008 [47] Brazil Case–control 57 37 ITA Nil 3.1 ± 3.2 1.4 ± 0.86 0.004 ↑ mg/L Both matched 
Heutling, 2008 [48] Turkey Interventional 21 15 ITA Nil 4.43 ± 2.02 3.74 ± 1.69 >0.05 NSD mg/dl Both matched 
Gen, 2008 [49] Germany Case–control 83 39 ITA Nil 3.26 ± 2.33 1.61 ± 1.36 <0.001 ↑ mg/L Both matched 
Jakubowska, 2008 
[50] 
Poland Interventional 29 29 INA Nil 3.53 ± 3.64 3.86 ± 4.27 >0.05 NSD mg/L Both matched 
Zwirksa-Korczala, 
2008 [51] 
Poland Case–control 40 20 ITA 
Lean 
Obese 
1.8 ± 0.3 
3.4 ± 1.6 




Age matched;  
BMI matched (lean) 
Çapoğlu, 2009 [52] Turkey Case–control 46 20 ITA Nil 2.0 ± 4.2 0.9 ± 1.0  NSD ** mg/L Both matched 
Kaya, 2009 [53] Turkey Case–control 60 60 ITA Nil 4.4 ± 1.6 1.5 ± 0.6 <0.01 ↑ mg/dl Both matched 
Chen, 2009 [54] Taiwan Case–control 155 37 ITA Nil 2.31 ± 0.51 (SE) 0.97 ± 0.2 (SE) 0.0159 ↑ mg/L Both matched 
Samy, 2009 [55] Egypt Case–control 108 75 Hs-ELISA 
BMI < 27 
BMI ≥ 27 
1.67 ± 0.23 
3.45 ± 0.35 
1.04 ± 0.25 
1.15 ± 0.22 
<0.0001 ↑ mg/L Both matched 
Soares, 2009 [56] Brazil Case–control 40 50 CLIA Nil 2.03 ± 2.7 3.32 ± 3.72 0.97 NSD mg/L Both matched 
Verit, 2009 [57] Turkey Case–control 52 48 
Spectro-pho-
tometry 
Nil 1.6 ± 0.6 0.4 ± 0.5 <0.0001 ↑ mg/L Both matched 
Gowri, 2010 [58] Oman Case–control 57 57 ITA Nil 5.41 ± 4.84 4.76 ± 4.54 0.461 NSD mg/L Both matched 
Nikołajuk, 2010 [59] Poland Case–control 78 34 ITA Lean Obese 
0.67 ± 0.50 
1.16 ± 0.74 
0.47 ± 0.22 
1.20 ± 0.83 
>0.5 NSD mg/L Both matched 
Tan, 2010 [60] UK Case–control 21 39 ITA Nil 3.3 (2.4–5.5) 1.3 (0.5–2.5) <0.01 ↑ mg/L Both matched 





Turkey Case–control 91 51 INA Nil 5.1 +3.9 3.5 ± 1.3 0.004 ↑ mg/L Both matched 
Caglar, 2011 [62] Turkey Case–control 61 21 Not specified Nil 0.6 [0.2–4.6] 1.3 [0.2–18.6] <.05 ↑ mg/L Both matched 
Fulghesu, 2011 [63] Italy Case–control 44 55 Hs-ELISA IR PCOS 0.55 [0.05–1.66] 0.139 [0.04–1.77] <0.005 ↑ *** ng/ml Both matched 
Hu, 2011 [64] China Case–control 85 65 INA Nil 1.9 ± 2.0 0.9± 0.8 0.009 ↑ mg/L Both matched 
Li, 2011 [65] UK Case–control 27 25 ITA Nil 2.2 [0.2–14.5] 0.8 [0.1–9.6] 0.017 NSD* mg/L Age, BMI adjusted 
Lindholm, 2011 [66] Sweden Case–control 30 20 ITA 
Lean 
OWT 
1.10 ± 0.99 
4.31 ± 3.16 
- 





BMI, matched (obese) 
             
Mannerås-Holm, 2011 
[67] 
China Case–control 70 30 ITA Nil 1.96 ± 1.92 1.00 ± 1.11 0.598 NSD* mg/L Both matched 
Ngo, 2011 [68] Australia Case–control 27 20 Not specified Nil 1.5 <0.25, 5.7> 0.4 <0.1–18> 0.008 ↑ mg/L Both matched 
Torun, 2011 [69] Turkey Case–control 30 20 Not specified Nil 0.22 ± 0.2 0.13 +0.1 0.3 NSD mg/L Both matched 
Xiong, 2011 [70] Chin Case–control 86 51 CLIA Nil 2.53 ± 2.97 0.95 ± 1.14 0.001 ↑ mg/L Both matched 
Yang, 2011 [71] China Case–control 133 116 ITA Nil 0.49 ± 0.88 1.46 ± 2.29 <0.05 ↑ mg/L Both matched 
             
Deveer, 2012 [72] Turkey Case–control 25 25 ITA Nil 1.0 [1.0–12.0] 1.0 [1.0–19.0] 0.286 NSD mg/L Both matched 
Elkholi, 2012 [73] Egypt Case–control 63 45 INA 
NIR GO  
IR AO 




>0.05 NSD  mg/dl Both matched 
Güdücü, 2012 [74] Turkey Case–control 62 40 ITA Nil 0.27 ± 0.28 0.19 ± 0.25 0.046 ↑ mg/L Both matched 
Iuhas, 2012 [75] Romania Case–control 31 29 Not specified Nil 3.22 ± 0.76 3.33 ± 0.83 0.60 * NSD * mg/L Both matched 
Kim, 2012 [76] Korea Case–control 115 103 Not specified Nil 0.24 ± 0.67 0.14 ± 0.46 0.231 NSD ** mg/L 
Age, not matched 
BMI, matched 
Rashad, 2012 [77] Egypt Case–control 107 92 Hs-ELISA Nil 1.0 ± 0.19 0.79 ± 0.1 <0.05 ↑ mg/L Both matched 







0.0001 ↑ mg/L Both matched 
Dehdashtihaghighat, 
2013 [79] 
Iran Case–control 42 42 ITA Nil 4.7 ± 1.5 0.00 0.039 ↑ mg/L Both matched 
Xia, 2013 [80] China Case–control 59 57 ITA Nil 1.58 ± 0.63 1.07 ± 0.47  <0.01 ↑ mg/L Both matched 
Kahal, 2013 [81] UK Case–control 19 17 Not specified Nil 6.2 ± 8.7 5.1 ± 3.4 >0.05 NSD mg/L Both matched 
Rey-Roldan, 2013 [82] Argentina Case–control 20 20 ITA Nil <<5.1>> <<0.8>> <0.0001 ↑ mg/L Both matched 
Tan, 2013 [83] UK Case–control 83 39 ITA Nil 2.8 (1.5–4.6) 1.3 (0.6–2.3) <0.01 ↑ mg/L Both matched 
Yildir, 2013 [84] Turkey Case–control 34 20 INA Nil 4.75 ± 3.99 3.76 ± 1.83 0.151 NSD mg/L Both matched 
Covington, 2014 [85] USA Interventional 8 8 CLIA Nil 3.8 ± 5.2 4.6 ± 6.1 0.79 NSD mg/L Both matched 
Guducu, 2014 [86] Turkey Case–control 58 34 ITA Nil 2.21 ± 3.8 1.69 ± 3.56 0.174 NSD mg/L Both matched 
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Kurt, 2014 [87] Turkey Case–control 62 60 INA 
Obese 
Lean 
6.0 ± 0.8 
2.8 ± 0.6 
3.4 ± 0.6 
2.8 ± 0.6 
<0.001 
<0.001 
↑ mg/L Both matched 
Porwal, 2014 [88] India Case–control 41 40 ITA Nil 3.76 ± 3.60 1.38 ± 1.48 <0.05 ↑ mg/L Both matched 
Sahin, 2014 [89] Turkey Case–control 91 53 ITA Nil 0.43± 0.67 0.15± 0.25 0.007 ↑ mg/L Both matched 
Stabile, 2014 [90] Italy Interventional 15 15 ITA Nil 0.27± 0.19 0.11 ± 0.1 <0.01 ↑ mg/L Both matched 
Sumithra, 2014 [91] Greece Case–control 61 61 ITA Nil 4.35 ± 4.16 0.40 ± 0.22 <0.001 ↑ mg/L 
Age Matched 
BMI adjusted 
Barcellos, 2015 [92] Brazil Case–control 25 23 Hs-ELISA Nil 0.9 [0.1–5.7] 0.5 [0.1–4.6] 0.361 NSD mg/L Both matched 
Daskalopoulos, 2015 
[93] 





9.01 ± 0.85  
4.13 ± 0.68  
3.5 ± 0.82 
2.98 ± 0.6 
3.09 ± 0.53 >0.05 NSD mg/L Both matched 
Demir, 2015 [94] Turkey Case–control 35 35 ITA Nil 0.3 ±0.4 0.1 ±0.2 0.001 ↑ mg/L Both matched 
Güdücü, 2015 [95] Turkey Case–control 35 30 ITA Nil 2.03 ± 3.59 1.68 ± 3.76 0.197 NSD mg/L Both matched 
Santos, 2015 [96] Brazil Case–control 20 20 CLIA 
BMI < 25 
BMI > 25 
2.63 ± 0.65 
2.35 ± 0.55 
0.63 ± 0.37 
0.82 ± 0.48 
0.01 
0.01 
↑ mg/L Both matched 
Sharma, 2015 [97] India Case–control 100 50 Hs-ELISA Nil 2.17 ± 0.30 2.27 ± 0.95 0.74 NSD mg/L Both adjusted 




2.78 ± 3.20 
4.06 ± 3.52 
0.77 ± 2.66 
2.58 ± 3.09 
4.037 ± 3.18 




NSD mg/L Both matched 
Calan, 2016 [99] Turkey Case–control 90 80 ITA Nil 1.49 ± 0.50 0.56 ± 0.49 <0.001 ↑ m/L Both matched 
Durmus, 2016 [100] Turkey Case–control 76 38 INA 
Overall 
BMI < 25 










NSD mg/dl Both matched 
Isıka, 2016 [101] Turkey Case–control 41 32 ITA Nil 5.46 ± 4.72 2.86 ± 4.59 <0.001 ↑ mg/L Both matched 
Kumar, 2016 [102] India Case–control 80 80 ITA Nil 8.5 ± 2.7 1.9 ± 1.2 0.0001 ↑ mg/L Both matched 
Kume, 2016 [103] Turkey Case–control 152 152 ITA Nil 0.76 ± 0.34 0.47 ± 0.22 <0.001 ↑ mg/L Both matched 
Mishra, 2016 [104] India Case–control 44 45 ITA Nil 4.21 ± 3.5 2.72 ± 1.78 <0.05 ↑ mg/L Both matched 
Ozturk, 2016 [105] Turkey Case–control 53 40 ITA Nil 2.1 ± 1.7 1.7 ± 1.0 0.095 NSD mg/L Both matched 
Temur, 2016 [103] Turkey Case–control 38 41 Not specified Nil 3.15 ± 2.23 1.18 ± 1.47 <0.001 ↑ mg/L Both matched 




3.72 ± 3.19 
2.07 ± 2.46 
0.018 
0.137 * 
NSD mg/L Both matched 
Deng, 2017 [108] China Case–control 30 0 ITA Nil 1.05 (0.218, 2.720) 0.19 (0.055–0.618) <0.001 ↑ mg/L Both matched 
Duan, 2017 [109] China Interventional 90 85 ITA Nil 1.99 ± 2.12 0.89 ± 0.65 0.047 ↑ mg/L 
Age, matched 
BMI adjusted 
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Abiad, 2018 [110] Lebanon Case–control 6 16 
Spectro-pho-
tometry 
BMI > 40 10.04 ± 5.85 6.63 ± 4.12 0.203 NSD mg/L Both matched 
Kalyan, 2018 [111] Bahrain Case–control 200 119 INA Nil 11.1 ± 1.1 15.5 ± 1.6 0.000 ↑ mg/L Both matched 
Shorakae, 2018 [112] Australia Case–control 49 22 ITA Nil 2.2 (3) 4.4 (6) >0.05 ↑ mg/L Both matched 
Arpacı, 2019 [113]  Turkey Case–control 38 48 ITA Nil 0.49 ± 0.55 0.18 ± 0.19 0.025 ↑ mg/L Both matched 
Demir, 2019 [114] Turkey Case–control 80 80 ITA Nil 1.22 ± 0.57 0.67 ± 0.20 <0.001 ↑ mg/L Both matched 




1.08 ± 0.83 
0.79 ± 0.39 
1.38 ± 1.04 
0.46 ± 0.46 
0.39 ± 0.36 
0.55 ± 0.55 
0.001 ↑ mg/dl Both matched 
Ganie, 2019 [116] India Case–control 82 179 Hs-ELISA 
Veg 
Non-veg 
3.83 ± 1.68 
2.38 ± 0.88 
2.19 ±1.48 
1.68 ± 1.52 
<0.01 
<0.01 
↑ mg/L Both matched 
Kim, 2019 [117] Korea Case–control 26 59 LIA Nil 0.03 (0.02–0.08) 0.04 (0.02–0.09) 0.420 NSD mg/dl Both matched 
Maidana, 2019 [118] Argentina Case–control 73 33 ITA Nil 2.38 (0.36–14.53) 11 (0.27–9.30) 0.005 NSD * mg/L Both adjusted 
Sánchez-Ferrer, 2019 
[119] 
Spain Case–control 126 159 ITA Nil 0.30 (0.16–0.44) 0.24 (0.20–0.30) 0.03 NSD * mg/dl Both adjusted 
Alissa, 2020 [120] KSA Case–control 82 82 ITA Nil 2.10 ± 0.4 5.1 ± 0.7 <0.0001 ↑ mg/L Both matched 
Godtfredsen, 2020 
[121] 
Denmark Case–control 90 35 INA Nil 1.0 (0.43–2.2) 0. 59 (0.29–1.23) 0.01 ↑ mg/L Both matched 
González, 2020 [122] USA Interventional 14 14 Hs-ELISA 
Lean 
Obese 
1.8 ± 0.2 
8.9 ± 2.0 
0.3 ± 0.1 
6.6 ± 1.5 
<0.05 
<0.02 
↑ mg/L Both matched 
Sadeghi, 2020 [123] Iran Case–control 120 60 Hs-ELISA Nil 4.00 ± 1.23 2.46 ± 0.95 <0.01 ↑ mg/ml Both matched 
CRP data presented as mean ± sd, <geometric mean>, median (IQR), median [range], median <unspecified range>, ((median)); mean {95% confidence interval} or <<average>>. Study 
design: for interventional studies, baseline pre-treatment CRP data are presented in this table. ↑ significantly elevated in PCOS women. * after adjustment for BMI. ** Trend towards 
increase, which is not statistically significant. *** elevated only in PCOS women with insulin resistance. Abbreviations: Hs, high sensitivity; ELISA, enzyme-linked immunosorbent 
assay; CLIA, chemiluminescence immunoassay; ITA; immunoturbidimetric assay; INA, immunonephelometric assay; LIA, latex immunoassay; IR, insulin resistant; NIR; non-insulin 
resistant; NSD, no statistically significant difference; NIR GO, non-insulin resistant and gynaecoid obesity, IR AO: insulin resistant and android obesity; Veg, vegetarian; OWT, over-
weight; NWT, normal weight; PHEN, PCOS phenotype.
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Mean ± SD CRP values were not provided in 22 studies 
[42,46,60,62,63,65,66,68,72,73,78,82,83,92,93,99,108,110,112,118,119,121]. Authors of these 
articles were contacted to provide the missing data, but no response was received despite 
several reminders. These studies were included in the systematic review but excluded 
from the meta-analysis. The remaining 63 studies had all the required CRP data and were 
used for meta-analysis of CRP results (Figure 1). 
2.1.4. Study Design 
Seventy-eight of the included articles were case–control cross-sectional studies. The 
remaining seven studies were interventional studies investigating the effect of different 
therapeutic interventions on inflammatory markers in PCOS women versus controls 
[43,48,50,85,90,109,122]. All these studies provided baseline data for PCOS women versus 
controls, which were suitable for this systematic review. 
2.1.5. Participants 
All studies used appropriate selection for their participants, which met our inclusion 
criteria. Rotterdam ESHRE/ASM criteria were used in all 85 studies for the diagnosis of 
PCOS. All participants were in childbearing age between 15–45 years, had no endocrino-
logical disease, were not pregnant at time of participation and were not on any medication 
that might affect the level of inflammatory markers in the preceding three months. 
2.1.6. CRP Kits 
Several high sensitivity (hs) CRP assays have been utilised in different studies as il-
lustrated in Table 1. The most used assay was immunoturbidimetric assay (ITA) (44 stud-
ies), followed by the immunonephelometric assay (INA) (13 studies). Other CRP assays 
include hs-ELISA (nine studies), chemiluminescence immunoassay (ECLIA) (six studies), 
hs-EIA (one studies), latex immunoassay (LIA) (one study), and mass spectrometry (two 
studies). The assay was not specified in nine studies, but the authors stated that they used 
a high sensitivity CRP assay (Table 2). 
Hs-ELISA is known for its relative ease of use, accuracy, and low cost. Its main draw-
back is its inflexibility to reagents and limited accuracy in markedly low concentrations 
(>1 μg/L). Only two studies used mass spectrometry, which is the most accurate measure-
ment. ITA and INA, which are the most used assays, provide excellent sensitivity with a 
detection time of < 1h [124]. However, these methods require relatively expensive, com-
plex, and require an inflexible set of reagents. 
2.2. Systematic Review 
2.2.1. CRP Results 
Serum CRP level was measured in 85 comparative studies (n = 9880), of which 53 
reported significantly higher levels in PCOS women (n = 5656) compared to healthy con-
trols (n = 4224). Details of CRP results of all 85 studies are summarised in Table 1. BMI of 
participants was either matched on selection (79 studies) or adjusted for during statistical 
analysis (six studies) concluding that the difference in CRP was attributed to PCOS status 
rather than obesity (Table 1). Age was matched for all studies apart from two studies 
[32,68]. 
Five other studies reported a statistically significant increase in serum CRP level 
among the PCOS women (n = 327) compared with healthy controls (n = 276), but after 
adjustment for BMI the difference was no longer statistically significant [65,67,75,118,119]. 
Two other studies showed a higher trend of serum CRP levels in PCOS women (n = 
161) compared to healthy controls (n = 123), but this did not reach statistical significance 
[52,76]. The remaining 25 studies failed to demonstrate any statistically significant differ-
ence in serum CRP levels between PCOS women and healthy controls. Of these, seven 
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studies reported statistically significant increase in other inflammatory markers as de-
scribed below [49,50,59,67,69,85,86]. 
To further investigate the effect of obesity as a main confounder on inflammatory 
status, we separately looked at eleven studies that stratified their participants according 
to BMI [51,55,59,66,78,87,96,98,100,115,122] and two studies that included only obese par-
ticipants only [45,110] (Table 1). Ten of the eleven studies stratifying PCOS group accord-
ing to BMI, revealed significantly higher circulating CRP in obese/overweight versus non-
obese PCOS women, while one study showed no difference [96]. On the other hand, eight 
studies comparing between BMI strata in the control group reported higher CRP levels in 
the higher BMI group [51,59,78,87,98,100,115,122], while two studies revealed no differ-
ence [55,96]. Comparison between different BMI strata between PCOS women and con-
trols is provided in the meta-analysis section below. 
2.2.2. IL-6 Results 
Circulating IL-6 was measured in 16 articles, of which five reported significantly 
higher levels in PCOS women compared to healthy controls (Table 3) [53,55,70,73,116]. 
The remaining 11 studies found no significant difference in circulating IL-6 between PCOS 
and non-PCOS women [45,48–50,56,59,63,67,82,92,96]. 
2.2.3. TNF-α Results 
Serum TNF-α concentration was measured in 12 studies with conflicting results  
(Table 3). While six studies reported higher serum TNF-α levels in PCOS women versus 
healthy controls [50,55,63,70,103,116], six studies showed no difference between the two 
groups (Table 3) [45,56,67,83,92,96]. 
2.2.4. White Cell Count (WCC) 
Eight studies (n = 1026) assessed WCC in PCOS women (n = 610) versus healthy con-
trols (n = 416) [46,47,70,77,85,87,98,101]. Of these, seven studies reported significantly 
higher WCC in PCOS versus control participants, while one study showed no difference 
between the two groups (Table 3) [70]. 
2.2.5. Adiponectin 
Eight studies including 892 participants assessed circulating adiponectin, with six 
showing significantly lower levels in PCOS women (n = 383) versus controls (n = 355) 
[50,51,63,73,112,116,123] and two reporting no difference between the two groups (PCOS, 
n = 100; control, n = 54) (Table 3) [45,83].
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Table 3. Characteristics of 45 studies with other inflammatory markers. 





CRP IL-6 TNF Adiponectin 
Other markers Age, BMI matching 
Marker  level  







Age, BMI matched 





Age, BMI matched 
Aydogdu, 2012 [33] Turkey 40 40 ↑ – – – PTX-3 ↑ Age, BMI matched 
Moran, 2007 [45] Australia 17 15 NS NSD NSD NSD – – PCOS older, BMI > 35 
Ruan, 2007 [46] China 74 51 ↑ – – – WCC  ↑ Age, BMI matched 





Age, BMI matched 
Gen, 2008 [49] Turkey 21 15 NS NSD – – Visfatin ↑ Age, BMI matched 
Jakubowska, 2008 [50] Poland 29 29 NS NSD ↑ ↓ -  Age, BMI matched 











Age, BMI matched 
Çapoğlu, 2009 [52] Turkey 46 20 NS – – – Resistin  ↓ Age, BMI matched 
Kaya, 2009 [53] Turkey 60 60 ↑ ↑ – – Il-18  ↑ Age, BMI matched 
Samy, 2009 [55] Egypt 108 75 ↑ ↑ ↑ – – – 
Age matched; BMI strati-
fied 
Soares, 2009 [56] Brazil 40 50 NS NSD NSD – – – Age, BMI matched 
Nikołajuk, 2010 [59] Poland 78 34 NS NSD – – 
SPG130  
sIL-6R   
↑ 
↓ 
Age, BMI matched 
Tan, 2010 [60] UK 21 39 ↑ – – – Omentin  ↑ Age, BMI matched 
Fulghesu, 2011 [63] Italy 44 55 ↑ NSD ↑ ↓ 
Leptin  





Age, BMI matched 
Hu, 2011 [64] China 85 65 ↑ – – – MCP-1  ↑  
Mannerås-Holm, 2011 [67] China 70 30 NS* NSD NSD – PAI-1   ↑ Age, BMI matched  
Ngo, 2011 [68] Australia 27 20 ↑ – – – Vit. D  ↓ Age, BMI matched 
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Age, BMI Matched 
Xiong, 2011 [70] China 86 51 ↑ ↑ ↑ – 
WCC  
Neutrophil count  
Lymphocyte count  







Age, BMI matched 
Yang, 2011 [71] China 133 116 ↑ – – – C3 ↑ 
Age, 
BMI adjusted 








Age, BMI matched 





Age, BMI matched 
Dehdashtihaghighat, 2013 [79] Iran 42 42 ↑ – – – C3  NSD Age, BMI matched 





Age, BMI matched 
Rey-Roldan, 2013 [82] Argentina 20 20 ↑ NSD – – IL-6 D NSD Age, BMI matched 





Age, BMI matched 
Covington, 2014 [85] USA 8 8 NS – – – WCC ↑ Age, BMI matched 
Guducu, 2014 [86] Turkey 58 34 NS – – – PTX-3 ↓ Age, BMI matched 









Age matched; BMI strati-
fied 
Barcellos, 2015 [92] Brazil 25 23 NS NSD NSD –   
Age matched; BMI strati-
fied 
Güdücü, 2015 [95] Turkey 35 30 NS – – – Chemerin  NSD 
Age matched, BMI ad-
justed 
Santos, 2015 [96] Brazil 20 20 ↑ NSD NSD – –  
Age matched; BMI strati-
fied 
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Age, BMI adjusted 
Calan, 2016 [99] Turkey 90 80 ↑ – – – MIF  ↑ Age, BMI matched 









Age, BMI matched 
Kume, 2016 [103] Turkey 152 152 ↑ – ↑ – –  Age, BMI matched 





Age, BMI matched 
Deng, 2017 [108] China 30 0 ↑ – – – IP-10  ↑ Age, BMI matched 
Shorakae, 2018 [112] Australia 49 22 ↑ – – ↓ –  Age, BMI matched 
Arpacı, 2019 [113]  Turkey   ↑ – – – Neuregulin-1 ↑ Age, BMI matched 
Demir, 2019 [114] Turkey 80 80 ↑ – – – Fractalkine  ↑ Age, BMI matched 







Age, BMI matched 
Sadeghi, 2020 [123] Iran 120 60 ↑ – – ↓ CTRP6 b  ↑ Age, BMI matched 
↑ significantly elevated in PCOS women, ↓ significantly reduced in PCOS women. Abbreviations: NSD, no significant difference between PCOS and control; sVCAM, soluble vascular 
cell adhesion molecule; sICAM, soluble intercellular adhesion molecule; ADMA, Asymmetrical dimethylarginine; SDMA, WCC, white cell count; Symmetrical dimethylarginine; sE-
selectin, soluble endothelial leukocyte adhesion molecule; PAI-1, plasminogen-activated inhibitor; SPG, soluble glycoprotein; sIL-6R, soluble IL-6 receptor; TGF, transforming growth 
factor; Vit, Vitamin; MCP-1, monocyte chemoattractant protein 1; TAS, total antioxidant status; TOS, total oxidative stress, OSI, oxidative stress index, LOOH, lipid hydroperoxide; 
C3, Complement C3; PTX-3, Pentraxin 3; MIF, Macrophage migration inhibitory factor; XO, xanthine oxidase activity, SOD, superoxide dismutase activity; NLR, neutrophil lymphocyte 
ratio; GGT, gamma-glutamyl transferase; IMA, Ischaemia-modified albumin; OS, oxidative stress; IP-10, Interferon g-induced protein 10 kDa; CTRP6, C1q/TNF-α-related protein 6. 




2.3.1. Primary Outcome: CRP 
Overall CRP Pooled Analysis 
Pooled analysis of 63 studies (n = 7206) with relevant data, showed significantly 
higher serum CRP levels in PCOS women (n = 4086) versus controls (n = 3120) (SMD 1.26, 
95% CI, 0.99, 1.53; z = 9.60; p = 0.00001; I2 = 96%). Heterogeneity between studies was high 
(Figure 2). 
 
Figure 2. Overall CRP pooled analysis of 63 studies. 
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Studies Using mg/L as a Unit of CRP Measurement 
Data from 58 studies (n = 6842) using mg/L for CRP measurement showed signifi-
cantly higher circulating CRP in PCOS women (n = 3884) versus controls (n = 2958) (SMD 
1.32, 95% CI, 1.03, 1.61; z = 8.89; p = 0.00001; I2 = 96%). 
Sensitivity Analysis of High-Quality Studies Including Only Non-Obese Participants 
(BMI < 30) 
This analysis included 35 studies scoring ≥7 on the modified New-castle Ottawa scale 
and providing data for women with BMI < 30 kg/m2 (n = 4556). We only analysed data of 
non-obese participants to remove the known confounding effect of obesity on CRP. 
Pooled analysis from these studies still showed significantly higher circulating CRP in 
PCOS women (n = 2579) compared to controls (n = 1977) (SMD 1.80, 95%CI, 1.36, 2.25; z = 
7.97; p < 0.00001; I2 = 97%). (Figure 3). 
 
Figure 3. CRP sensitivity analysis of 35 high quality studies including non-obese women. 
Studies Including Only Obese Participants (BMI > 30) 
This analysis included seven studies presenting CRP data (mean ± SD) for obese par-
ticipants (n = 343). Pooled analysis revealed significantly higher CRP levels in 192 PCOS 
women versus 151 healthy controls (SMD 0.96, 95% CI, 0.01, 1.91; z = 1.98; p = 0.05; I2 = 
98%). (Figure 4). The magnitude of this difference was smaller than that between of nor-
mal weight groups. 




Figure 4. CRP subgroup analysis of 7 studies including obese women. 
2.3.2. IL-6 Meta-Analysis. 
Nine studies involving 894 participants presented IL-6 data suitable for meta-analy-
sis. Pooled analysis of these studies showed significantly higher serum IL-6 levels in 476 
PCOS women versus 418 controls (SMD 0.50, CI 95%, 0.09, 0.90; z = 2.40; p = 0.02; I2 = 87%) 
(Figure 5). 
 
Figure 5. IL-6 metanalysis of 9 studies. 
2.3.3. TNF-α Meta-Analysis 
TNF-α data were available from nine studies comparing PCOS women (n = 552) ver-
sus healthy controls (n = 561). Pooled analysis revealed no significant difference between 
the two groups (SMD 0.77, 95% CI, −0.25, 1.79; z = 1.49; p = 0.14; I2 = 98%) (Figure 6). 
 
Figure 6. TNF-α metanalysis of 9 studies. 
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2.3.4. Adiponectin Meta-Analysis 
Pooled analysis of four studies (n = 538) revealed significantly lower serum adiponec-
tin levels in PCOS women (n = 250) compared to healthy controls (n = 288) (SMD -1.48 95% 
CI; −2.48, −0.14; z = 2.91; I2 = 87%) (Figure 7) 
 
Figure 7. Adiponectin metanalysis of 4 studies. 
3. Discussion 
To the best of our knowledge, this is the largest systematic review and meta-analysis 
with nearly 10,000 participants, that investigates the chronic inflammatory status in PCOS 
women. We have analysed 85 studies (n = 9880) comparing circulating CRP and other 
inflammatory markers in PCOS women (n = 5656) versus healthy controls (n = 4224). Alt-
hough, there was some conflicting results with CRP from different studies, most publica-
tions reported significant elevation of circulating CRP in PCOS women compared to 
healthy controls (SMD 1.37). Furthermore, sensitivity meta-analysis of CRP data in non-
obese women from 35 studies with low risk of bias (n = 4556) still revealed a significantly 
elevated CRP in PCOS women versus healthy controls with an SMD of 1.80. On the other 
hand, subanalysis of CRP data in obese women revealed a much less pronounced CRP 
elevation (SMD 0.96) in PCOS women. These findings support the hypothesis that that the 
chronic inflammation observed in PCOS women is independent of obesity. 
While meta-analysis of IL-6 revealed significantly higher levels in PCOS women, 
pooled analysis of TNF-α showed no significant difference between the two groups. On 
the other hand, most studies reported that WCC was consistently elevated and adiponec-
tin was consistently reduced in PCOS women versus controls providing more evidence 
for an ongoing inflammatory process in this population. 
3.1. Comparison with Previous Studies 
Our results are consistent with the previous systematic review published in 2011 by 
Escobar-Morreale et al., which reported a two-fold increase in CRP [27]. However, unlike 
this previous review, which included studies adopting different sets of diagnostic criteria 
for PCOS, we adhered only to the universally accepted Rotterdam criteria thereby reduc-
ing heterogeneity. Furthermore, Escobar-Morreale et al. only used PubMed search engine 
to identify studies, while we have applied a more comprehensive search including all 
available electronic databases as detailed above. In addition, we performed risk of bias 
assessment of selected articles to identify high quality studies for a sensitivity analysis, 
which is lacking in the previous review. Moreover, our much larger number of PCOS par-
ticipants allowed us to undertake sub-analysis for non-obese PCOS women, thereby elim-
inating the confounding effect of obesity on the inflammatory status of participants. Ad-
ditionally, our review included more recent studies, which utilised advanced CRP assays 
with much improved sensitivity and accuracy. We also assessed the status of the anti-
inflammatory factor adiponectin in PCOS women, which was not evaluated in the previ-
ous review. 
Although, 32 of the 85 studies included in our review did not show a significant ele-
vation in circulating CRP, some of these showed a trend of higher CRP, which did not 
reach statistical significance, possibly due to the small numbers included (type II error). 
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Furthermore, several studies showing no increase in CRP reported elevation of other 
markers such as IL-6, TNF-α other ILs and WCC. 
A possible explanation for the discrepancies in CRP results between studies could be 
the variation in phenotypes of PCOS women included in different studies. For instance, 
Daskalopoulos et al. reported that PCOS women with no hyperandrogenism had CRP 
levels comparable to healthy controls [93]. On the other hand, PCOS women with full 
features of the syndrome had a 3-fold increase in levels of CRP compared to PCOS women 
with normal androgen levels [93]. This is further supported by the hypothesis that excess 
androgens have been implicated as a possible underlying cause for chronic inflammation 
as discussed below [13]. 
3.2. Inflammatory Status in PCOS Women 
Despite some discrepancy in the literature as discussed above, our meta-analysis pro-
vides strong evidence for a chronic inflammation in women with PCOS as evidenced by 
the significant elevation of circulating CRP in most reviewed studies. Notably, the eleva-
tion in circulating CRP is only modest with levels not exceeding 5.0 mg/L in PCOS women 
in most studies indicating low-grade inflammation. The status of other main inflamma-
tory markers including IL-6 and TNF-α is still not clear with limited and conflicting data. 
However, the increased CRP provides an indirect evidence of increased IL-6 and TNF-α, 
which are the main mediators of CRP production in the liver. 
Our findings also confirm that the obesity-related increase in CRP is further en-
hanced by the presence of PCOS. However, whilst the elevation in circulating CRP in 
PCOS is evident in normal weight women, it is less pronounced in obese PCOS when 
compared to obese controls. This is consistent with several previous reports [42,125]. This 
led Gonzalez to hypothesize that CRP elevations attributable to PCOS may be obscured 
in the presence of obesity [126]. This suggests that CRP level may be a less sensitive single 
indicator of chronic inflammation in obese PCOS women. [126]. 
In addition to the increased inflammatory markers, our review has found reduced 
adiponectin, which is a well-known anti-inflammatory factor, in PCOS women. Some 
studies have also reported a decrease in Pentraxin -3 (PTX3) [30,86], which is structurally 
related to CRP and plays a regulatory role in inflammation with a possible protective ef-
fect against atherosclerosis and cardiovascular risks [127]. All these findings indicate that 
the ongoing inflammation in PCOS is a double-sided process with increased proinflam-
matory factors as well as reduced inflammatory protective factors. 
More evidence of the inflammatory status in PCOS independent of obesity comes 
from two studies reporting the effect of weight loss on inflammatory markers in obese 
women [45,110]. Whilst weight loss was associated with beneficial lowering effect on in-
flammatory markers in both PCOS and non-PCOS obese women, this effect was less evi-
dent and slower in the PCOS group. These findings provide further evidence supporting 
the hypothesis that chronic inflammation is related to PCOS pathology independent of 
obesity. 
3.3. Mechanisms of Inflammation in PCOS 
The exact mechanism of inflammation in PCOS women is largely unknown. Excess 
adiposity, which is very common in PCOS women is a well-known proinflammatory con-
dition, in which hypertrophied adipocytes and adipose tissue-resident immune cells con-
tribute to chronic low-grade inflammation [128]. However, other factors must account for 
inflammation in lean PCOS women and for the greater than expected inflammation in 
obese PCOS women. 
There is limited evidence suggesting a genetic basis for the chronic low-grade inflam-
mation observed in PCOS women. Few studies have reported an association between 
PCOS and proinflammatory genotypes including those encoding TNF-α, type 2 TNF re-
ceptor and IL-6 [129–131]. 
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PCOS-associated hyperandrogenism has also been suggested as a possible underly-
ing cause for adipose tissue inflammation. Deligeoroglou et al. [13] hypothesized that an-
drogen-induced adipocyte hypertrophy causes compression of stromal vessels leading to 
tissue hypoxia, which is known to trigger inflammation. 
3.4. The Role of CRP in PCOS Pathogenesis 
A significant body of evidence implicates androgen excess and insulin resistance in 
the pathogenesis of PCOS. Both androgen excess and insulin resistance are strongly asso-
ciated with chronic inflammation. Based on this and on the findings of our meta-analysis, 
we can conclude that androgen excess, insulin resistance and chronic inflammation, which 
are all interlinked are strongly associated with PCOS. The exact interaction between these 
three pathological entities and their exact role in the pathogenesis PCOS remain to be fur-
ther elucidated. 
3.4.1. Chronic Inflammation and Hyperandrogenism 
Current evidence strongly suggests a key role of adipose tissue in mediating chronic 
inflammation in obesity and diabetes [132,133]. In obesity, hypertrophied adipocytes and 
adipose tissue-resident immune cells (lymphocytes and macrophages) are the main 
sources of increased circulating proinflammatory cytokines. Furthermore, obesity-associ-
ated chronic inflammation, termed “metabolic inflammation,” is considered crucial in the 
pathogenesis of insulin resistance and type 2 diabetes (T2D) [128,133–136]. Given the well-
known link between obesity, T2D and PCOS, it is possible to hypothesis that adipose tis-
sue inflammation may play a crucial role in PCOS pathogenesis. 
We and others have previously provided evidence for adipose tissue as a possible 
source of excess androgen production in women with PCOS [14,15,137]. Furthermore, sev-
eral studies have reported a positive correlation between chronic low-grade inflammation 
and hyperandrogenism in PCOS [93]. Given the fact that adipose tissue is the site for both 
chronic inflammation and excess androgen production in PCOS, the causal relation be-
tween these two processes remains largely uncertain with limited conflicting literature 
data [12,13]. While Deligeoroglou et al. [13] reported that androgen excess could trigger 
inflammation (as explained above), González et al. [126] found that diet-induced inflam-
mation in PCOS women has been shown to directly invoke hyperandrogenism. The inter-
action between hyperandrogenaemia and adipose tissue inflammation in PCOS therefore 
remains to be further elucidated. Most previous research has focused on circulatory mark-
ers of inflammation in PCOS women with no studies involving adipose tissue [126]. Given 
the well-known role of adipose tissue in chronic inflammation and excess androgen pro-
duction, it will be crucial to study the inflammatory status in this tissue in PCOS in future 
research [132]. 
3.4.2. Chronic Inflammation and Insulin Resistance 
Insulin resistance has been reported in up to 70% of PCOS women [138], and insulin 
sensitivity is reduced by ~40% in PCOS women, independent of obesity [139]; although 
obesity further impairs insulin metabolism. The role of adipose tissue chronic inflamma-
tion in the development of insulin resistance is well established in obesity and T2D [133]. 
Two main adipose tissue-derived inflammatory cytokines have been implicated in insulin 
resistance including TNF-α and IL-6. TNF-α, which is primarily secreted by adipose tis-
sue-resident macrophages, was the first inflammatory cytokine to be implicated in the 
induction of insulin resistance [8,15,16]. TNF-α levels are positively correlated with other 
markers of insulin resistance [19]. In rodents, obese mice lacking either TNF-α or its re-
ceptor show protection against the development of insulin resistance [17]. The main mech-
anism by which TNF-α induces insulin resistance is by triggering post-receptor serine 
phosphorylation of insulin receptor substrate-1 (IRS-1) thereby interfering with the insu-
lin signalling pathway [22]. In addition, TNF-α is also known to promote lipolysis and the 
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secretion of free fatty acids, which contribute to an increase in hepatic glucose production 
[23]. It also downregulates adiponectin [26], which is an adipocyte-derived hormone that 
contributes to the maintenance of peripheral glucose and lipid homeostasis [27]. 
On the other hand, the role of IL-6 in insulin resistance is less clear with conflicting 
literature data. It has been hypothesized that the effect of IL-6 on insulin metabolism var-
ies according to the duration of IL-6 elevation (transient or chronic), the type of tissue and 
the metabolic state [133]. For instance, during exercise, a transient elevation of IL-6 in-
creases glucose uptake in the skeletal muscle as well as having an anti-inflammatory effect 
[140]. On the other hand, in adipose tissue and liver, IL-6 exerts proinflammatory activities 
and induces insulin resistance by upregulating suppressor of cytokine signalling 3 
(SOCS3), which is a protein that binds to and inhibits insulin receptor [141]. Additionally, 
it negatively regulates IRS-1 phosphorylation and transcription [142,143]. 
Based on the above, although the exact causal relation between chronic inflamma-
tion, insulin resistance and hyperandrogenism in PCOS is still unclear, there seems to be 
a vicious circle triad between these three elements of PCOS [112]. One possible hypothesis 
is that PCOS-related hyperandrogenism leads to adipose tissue inflammation with subse-
quent dysregulated adipokine secretion resulting in insulin resistance [112]. 
3.5. Limitations and Strengths 
The main limitation in this review is the high heterogeneity between studies and the 
small size of many of the reviewed studies. Heterogeneity is mainly due to the variation 
in laboratory methods used to measure CRP and other markers, the variation in age and 
BMI of participants and the possible variation in PCOS phenotypes. To minimise hetero-
geneity, we carried out a sensitivity analysis of high-quality studies including only non-
obese participants. 
The main strength of the review is the large number of participants approaching 
10,000. In all studies, CRP was measured early morning after an overnight fast. This helps 
to avoid the effect of circadian rhythm and the effect of food on CRP levels. 
3.6. CRP and Cardiovascular Risk 
According to the American Heart Association, elevated serum hs-CRP level is well-
established as a prognostic marker of cardiovascular disease with a cut-off value of 3 mg/L 
that can detect patients at high risk, while a level of 1–3 mg/L is associated with a moderate 
risk [144,145]. Although most studies in our review reported elevated circulating CRP, 
only 35 of the 85 reviewed studies reported levels mean or median levels higher than 3 
mg/L. Notably, the wide variation in CRP levels in different studies may limit our inter-
pretation of the results. Nevertheless, measuring CRP may be considered in addition to 
other cardiovascular prognostic markers in PCOS women to identify those with CRP lev-
els >3mg/L. Furthermore, it may be necessary to monitor PCOS women with increased 
CRP (>3mg/L) to detect an upward trend of CRP that would identify high-risk patients 
[144]. However, the marked biological variation should be taken into consideration when 
interpreting repeated CRP measurement . 
3.7. Implications for Treatment and Future Research 
It is tempting to hypothesize that drugs targeting chronic inflammation may reduce 
PCOS-associated cardiovascular risks. Preliminary data suggest that insulin sensitizing 
agents (e.g., metformin) may improve the inflammatory status in PCOS [43,90,146]; but 
the evidence is still inconclusive. Further research is required to understand the exact 
mechanisms and role of chronic inflammation in PCOS. 
Oral contraceptive pills (OCPs), which are commonly used in PCOS, have recently 
been found to increase serum CRP levels according to a recent systematic review [147]. 
We may therefore need to practice some caution when prescribing OCPs to PCOS women 
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or to consider alternative treatment options. Further research is required to assess this risk 
further. 
4. Materials and Methods 
This study has been conducted in line with the Preferred Reporting Items for System-
atic Reviews and Meta-Analysis (PRISMA) guidelines and was prospectively registered 
with PROSPERO (registration number CRD42018085211). 
4.1. Eligibility Criteria for Study Selection 
We considered all studies comparing serum CRP concentrations between PCOS 
women diagnosed according to ESHRE/ASRM Rotterdam criteria [6] versus healthy con-
trols. Only studies using high sensitivity CRP (hs-CRP) assays and matching and/or ad-
justing for BMI and age were included. In addition, the review included studies conducted 
on humans, written in English language, and involving non-pregnant women aged 15–45 
years who were drug naïve and with no history of any disorder that might affect their 
inflammatory markers. 
If more than one article by the same research group were identified, only the study 
with the larger sample size was included in the meta-analysis to avoid duplication of 
cases. 
4.2. Outcome Measures 
4.2.1. Main Outcome 
Serum CRP concentrations in PCOS women compared to controls. 
4.2.2. Secondary Outcome Measures 
These included other proinflammatory markers (e.g., IL-6, TNF-α, IL-18) and the 
anti-inflammatory factor adiponectin measured in the serum of PCOS women and com-
pared to controls. 
4.3. Search Strategy 
PUBMED, EMBASE and MEDLINE, SCOPUS, Dynamed, TRIP, scienceDirect and 
Cochrane Library were systematically searched starting from January 2000 to March 2020 
for pertinent studies; A Combination of these search terms was used ((exp “POLYCYSTIC 
OVARY SYNDROME”/OR exp “POLYCYSTIC OVARY SYNDROME”/di OR (Polycystic 
Ovary Syndrome).ti,ab OR ((Polycystic AND Ovary) AND Syndrome).ti,ab OR (Polycys-
tic Ovar*).ti,ab OR (Polycystic Ovar* Disease).ti,ab OR (PCOS).ti,ab) AND (((exp IN-
FLAMMATION/OR (Inflammation).ti,ab) AND (exp BIOMARKERS/OR (Bi-
omarkers).ti,ab)) OR (exp “C-REACTIVE PROTEIN”/OR (C Reactive Protein).ti,ab))) [DT 
FROM 2000] [Languages English]1. 
The search was conducted by a clinical Librarian (LS) and repeated by a second in-
dependent Librarian. Further manual search of references of selected articles was con-
ducted to identify eligible studies. 
4.4. Screening and Selection of Retrieved Studies 
Titles and abstracts of the articles retrieved by the above search were screened for 
relevance. Full texts of the relevant articles were further evaluated carefully, and eligible 
studies were selected according to the inclusion and exclusion criteria. This process was 
conducted by two independent reviewers (SA and SA) and in cases of disagreement, a 
consensus was reached after discussion between the two reviewers. 
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4.5. Assessment of Quality and Risk of Bias 
Modified New-Castle Ottawa scale was used for assessment of non-randomized tri-
als as recommended [148,149]. Three main aspects were evaluated in each study namely 
selection, comparability, and outcome with maximum score of four, two and three, re-
spectively. Selection was assessed on basis of accurate definition of cases, inclusion of se-
ries of cases, inclusion of community control and power calculation. Studies were 
awarded a maximum of two stars in comparability if proper matching and/or adjustment 
to main confounders—namely age and BMI of participants-was ensured. Three aspects of 
outcome were evaluated which were timing of blood sampling following eight to twelve 
hours of fasting, use of validated laboratory methods to detect inflammatory markers and 
clear statistical comparisons between PCOS and control groups. 
We included all retrieved eligible studies in our initial overall analysis. This was then 
followed by a sensitive analysis including only high-quality studies scoring at least 7 on 
the New-Castle Ottawa scale. 
4.6. Data Extraction and Analysis 
Data (mean ± sd) were extracted from the individual articles including age, BMI, 
CRP, and TNF-α, IL-6, and adiponectin. These data were entered into the RevMan soft-
ware (Review Manager, version 5.1, The Cochrane Collaboration, 2011; The Nordic 
Cochrane Centre, Copenhagen, Denmark) for meta-analysis. The standard mean differ-
ence (SMD) in CRP, TNF-α, IL-6 and adiponectin between PCOS women and healthy con-
trols was calculated. Statistical heterogeneity between studies was assessed by I-squared 
(I2) statistics and Chi square test. I2 values of ≥50% or chi square analysis larger than its 
degree of freedom was indicative of high heterogeneity [150]. When heterogeneity was 
significant, a random-effect model was used for meta-analysis. Fixed effect meta-analysis 
was used when there was no significant heterogeneity. 
For CRP, an initial overall meta-analysis was conducted for all included studies. Fur-
ther sensitive analysis of CRP data was conducted separately for high-quality studies scor-
ing ≥7 on the New-Castle Ottawa scale. In this meta-analysis, we included data for partic-
ipants with BMI < 30 kg/m2 to remove the confounding effect of obesity on CRP. Another 
sub-group meta-analysis was conducted for studies with CRP data for obese participants 
(BMI > 30 kg/m2). A further sub-analysis was conducted for studies using mg/L as the unit 
of CRP measurement. 
We used the standardized mean difference (SDM) model in this meta-analysis in 
view of the differences in the units of CRP measurement used across the included studies 
[151]. In contrast to the mean difference (MD), which is the difference in the means of the 
study and control groups, the SMD is the MD divided by the standard deviation (SD), 
derived from either or both of the groups [151]. In addition to being independent of the 
unit of measurement, the SMD has been found to be more generalizable [152] and an eas-
ier way to judge the magnitude of difference between the groups [152]. The general rule 
described by Cohen et al. suggests that an SMD of 0.2 represents a “small” difference, an 
SMD of 0.5 represents a “medium” difference, and an SMD of 0.8 represents a “large” 
difference [153]. 
5. Conclusions 
Our meta-analysis provides further strong evidence for a moderate elevation in cir-
culating CRP in PCOS women with a decline in adiponectin, which are indicative of a 
low-grade chronic inflammation. These changes are mainly attributable to PCOS, inde-
pendent of, but further accentuated by, obesity. The relevance of this small rise in CRP in 
relation to the cardiovascular risks remains unknown. Only limited and conflicting data 
are available on the status IL-6 and TNF-α. Further research is required to investigate the 
underlying molecular mechanisms of chronic inflammation at the cellular level, especially 
in adipose tissue. 
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